Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol ...

When Rita Hunter first asked to meet with me, I had no idea she had been diagnosed with Amyotrophic Lateral Sclerosis (ALS) ...

Amyotrophic lateral sclerosis (ALS) is a rare neurological disorder that affects specific nerve cells in the spinal cord known as motor neurons. Symptoms involve issues with swallowing and speech ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe e ...

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.

Researchers from the Structural Biology Brussels group at Vrije Universiteit Brussel (VUB) have uncovered a significant ...

Therapeutics announced it has concluded a Type C meeting with the FDA for PrimeC in the treatment of amyotrophic lateral ...

The global amyotrophic lateral sclerosis treatment market size was US$ 637.2 million in 2021. The global amyotrophic lateral sclerosis treatment market is forecast to grow to US$ 918 million by 2030, ...